NEW YORK (GenomeWeb News) - Aureus Pharma said today that Bristol-Myers Squibb will license three of its databases.
Under the agreement, BMS has renewed its license for Aureus’ AurScope GPCR, and it has signed new agreements to license the AurScope Kinase and Ion Channel Knowledge databases as well.
Aureus said its databases provide information on drug target classes and other pharma topics, including ADME and drug-drug interactions. This information has been mined from the scientific literature to help researchers design and prioritize experiments, the company said.
BMS and Aureus Pharma have been license partners since 2002.
Financial terms of the license were not released